# Evaluation of the Clinical Efficacy and Safety of Amlodipine 5mg/ Bisoprolol Fumarate 5mg /Perindopril Arginine 5mg Fixed-dose Combination in Capsule and Free Monotherapy at the Same Dose in Patients With Uncontrolled Essential Hypertension.

Study · id `cardio:ct-nct05288400` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05288400](<https://clinicaltrials.gov/study/NCT05288400>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05288400

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 150 participants.

## Technical summary

Registry record NCT05288400. Randomized; no masking; primary purpose treatment. Start 2018-05-14 (actual); primary completion 2018-12-18 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 150 participants (enrolled count; ClinicalTrials.gov record NCT05288400, source copy `cardio:ctgov-nct05288400-2025-06-05`, retrieved 2026-10-26)
- Started: 2018-05-14 (actual) (ClinicalTrials.gov record NCT05288400, source copy `cardio:ctgov-nct05288400-2025-06-05`, retrieved 2026-10-26)
- Primary completion: 2018-12-18 (actual) (ClinicalTrials.gov record NCT05288400, source copy `cardio:ctgov-nct05288400-2025-06-05`, retrieved 2026-10-26)
- Completion: 2018-12-18 (actual) (ClinicalTrials.gov record NCT05288400, source copy `cardio:ctgov-nct05288400-2025-06-05`, retrieved 2026-10-26)
- Countries: Russia (ClinicalTrials.gov record NCT05288400, source copy `cardio:ctgov-nct05288400-2025-06-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05288400-2025-06-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluation of the Clinical Efficacy and Safety of Amlodipine 5mg/ Bisoprolol Fumarate 5mg /Perindopril Arginine 5mg Fixed-dose Combination in Capsule and Free Monotherapy at the Same Dose in Patients With Uncontrolled Essential Hypertension.
- Condition: Essential Hypertension
- Intervention (Combination product): Amlodipine 5mg + bisoprolol fumarate 5mg + perindopril arginine 5mg
- Intervention (Drug): Norvasc 5mg tablet
- Intervention (Drug): Concor 5mg tablet
- Intervention (Drug): Coversyl 5mg tablet
- Lead sponsor: Servier
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)

## Provenance

Content hash: 80de776313f02b7d0d7cc01619fa7a04781ae8aeee5e43b15a9471a732e5e9bc
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
